ALSF launched the Crazy 8 Initiative to detail roadmaps toward cures for specific, hard-to-treat childhood cancers. This collaborative effort kicked off in the fall of 2018 with a meeting that brought together more than 90 top scientists from around the world providing expertise in eight key areas of need.

Neuroblastoma

• Yael Mosse, MD, Children's Hospital of Philadelphia (co-lead)
• Julie Park, MD, Seattle Children's Hospital (co-lead)
• Garrett Brodeur, MD, Children's Hospital of Philadelphia
• Hubert Caron, MD/PhD, F.Hoffmann - La Roche Ltd.
• Steven DuBois, MD, Dana-Farber Cancer Institute
• Martin Eilers, PhD, University of Wuerzburg
• Mike Hogarty, MD, Children's Hospital of Philadelphia
• Mark Lemmon, PhD, Yale University School of Medicine
• Kate Matthay, MD, University of California San Francisco
• Paul Sondel, MD/PhD, University of Wisconsin, Madison WI
• Frank Speleman, PhD, Ghent University
• John Maris, MD, Children's Hospital of Philadelphia (co-chair of Crazy 8)

Embryonal Brain Cancers

• Robert Wechsler-Reya, PhD, Sanford Burnham Prebys Medical Discovery Institute (co-lead)
• William Weiss, MD/PhD, University of California San Francisco (co-lead)
• Olivier Ayrault, PhD, Curie Institute
• Pratiti (Mimi) Bandopadhayay, MBBS/PhD, Dana-Farber Cancer Institute
• Livia Garzia, PhD, McGill University
• Annie Huang, MD/PhD, Hospital for Sick Children
• Duane Mitchell, MD/PhD, University of Florida
• Siddhartha Mitra, PhD, University of Colorado School of Medicine
• Paul Northcott, PhD, St. Jude Children's Research Hospital
• Jim Olson, MD/PhD, Fred Hutchinson Cancer Research Institute
• Rachael Sirianni, PhD, University of Texas Health Science Center at Houston
• Michael Taylor, MD/PhD, The Hospital for Sick Children

High Grade Gliomas (Including DIPG and Ependymoma)

• Suzanne Baker, PhD, St Jude Children's Research Hospital (co-lead)
• Michelle Monje, MD/PhD, Stanford University (co-lead)
• Oren Becher, MD, Northwestern/Lurie Children's
• Benjamin Deneen, PhD, Baylor College of Medicine
• David Ellison, MD, St. Jude Children's Research Hospital
• Mariella Filbin, MD/PhD, Dana-Farber Cancer Institute/Boston Children's Hospital
• David Jones, PhD, Hopp Children's Cancer Center (KiTZ)
• Stephen Mack, PhD, Texas Children's Hospital
• Hideho Okada, MD/PhD, University of California San Francisco
• Josh Rubin, MD/PhD, Washington University School of Medicine
• Rosalind Segal, MD/PhD, Dana-Farber Cancer Institute
• Uri Tabori, MD/PhD, Hospital for Sick Children
• Nada Jabado, MD/PhD, McGill University (co-chair of Crazy 8)

Leukemia

• Adolfo Ferrando, MD/PhD, Columbia University (co-lead)
• Soheil Meshinchi, MD/PhD, Fred Hutchinson Cancer Research Center (co-lead)
• Charles Mullighan, MBBS/MD, St. Jude Children's Research Hospital (co-lead)
• Marie Bleakley, MD/PhD, Fred Hutchinson Cancer Research Center
• Stephanie Halene, MD/PhD, Yale University School of Medicine
• Stephen Hunger, MD, Children's Hospital of Philadelphia
• E. Anders Kolb, MD, Nemours/Alfred I duPont Hospital for Children
• Jatinder Lamba, PhD, University of Florida
• Thomas Look, MD, Dana Farber Cancer Institute
• Akiko Shimamura, MD/PhD, Dana Farber/Boston Children's Cancer and Blood Disorders Center
• Jun Yang, PhD, St. Jude Children's Research Hospital

Fusion Positive Sarcoma

• Olivier Delattre, MD/PhD, Inserm - Institut Curie (co-lead)
• Kim Stegmaier, MD, Dana-Farber Cancer Institute (co-lead)
• Scott Armstrong, MD/PhD, Dana- Farber Cancer Institute
• Alex Bishop, DPhil, Greehey CCRI, UT Health San Antonio
• Lee Helman, MD, Children's Hospital Los Angeles
• Heinrich Kovar, PhD, Children´s Cancer Research Institute
• Andrew Kung, MD/PhD, Memorial Sloan Kettering Cancer Center
• Marc Ladanyi, MD, Memorial Sloan Kettering Cancer Center
• Beth Lawlor, MD/PhD, University of Michigan Rogel Cancer Center
• Stephen Lessnick, MD/PhD, Nationwide Children's Hospital
• Miguel Rivera, MD, Massachusetts General Hospital / Harvard Medical School

Fusion Negative Sarcoma

• Richard Gorlick, MD, MD Anderson Children's Cancer Hospital (co-lead)
• Alejandro Sweet-Cordero, MD, University of California San Francisco (co-lead)
• Adrienne Flanagan, MB/BCH/BAO/FRCPath/PhD/FMedSci, University College London - UCL Cancer Institute
• Mark Hatley, MD/PhD, St. Jude Children's Research Hospital
• Katherine Janeway, MD/MMSc, Dana-Farber Cancer Institute
• Rosie Kaplan, MD, Pediatric Oncology Branch/National Cancer Institute/NIH
• Javed Khan, MD, NIH/NCI/Center for Cancer Research
• David Langenau, PhD, Massachusetts General Hospital
• Brendan Lee, MD/PhD, Baylor College of Medicine
• Nicola Mason, B.Vet.Med./PhD, University of Pennsylvania
• Troy McEachron, PhD, University of Southern California
• Poul Sorensen, MD/PhD, BC Cancer Research Centre
• Lisa Wang, MD, Baylor College of Medicine

Big Data

• Casey Greene, PhD, Alex's Lemonade Stand Foundation (co-lead)
• Trevor Pugh, PhD, FACMG, Princess Margaret Cancer Centre (co-lead)
• Stephanie Hicks, PhD, Johns Hopkins University
• John Hogenesch, PhD, Cincinnati Children's Hospital Medical Center
• Larry Hunter, PhD, University of Colorado School of Medicine
• Claudia Kleinman, PhD, McGill University
• Olena Morozova, PhD, University of California Santa Cruz
• Sofie Salama, PhD, University of California Santa Cruz
• Pavel Sumazin, PhD, Baylor College of Medicine
• Sam Volchenboum, MD/PhD, University of Chicago
• Jinghui Zhang, PhD, St. Jude Children's Research Hospital

Catalyzing Clinical Trials

• Crystal Mackall, MD, Stanford University (co-lead)
• Mark Kieran, MD/PhD, Bristol-Meyers Squibb (co-lead)
• Peter Adamson, MD, Children's Hospital of Philadelphia
• Lia Gore, MD, Children's Hospital Colorado
• Wendy London, PhD, Dana-Farber/Boston Children's Cancer & Blood Disorders Center
• Melinda Merchant, MD/PhD, AstraZeneca
• Maureen O'Brien, MD/MS, Cincinnati Children's Hospital Medical Center
• David Poplack, MD, Baylor College of Medicine